News
The drugmaker Novo Nordisk is slated to report its second-quarter financial results early Wednesday, after shares plunged ...
The Trump administration is planning to pilot covering weight loss drugs. A longtime healthcare exec moves to a strategic advisory role at General Catalyst.
The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.
Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according to the Cleveland Clinic. It’s a condition often linked to obesity, ...
Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...
A study published in Cell Metabolism looks at the effects of semaglutide on skeletal muscle mass in mice. Prof Lora Heisler, Director of Research, Rowett Institute, University of Aberdeen, Rowett ...
New lawsuits target pharmacies producing compounded versions of semaglutide ‘under the fake guise of personalization,’ the Danish drugmaker said ...
Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...
Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment ...
Noom claims its microdose approach allows users to lose up to 11 pounds (around 5kg) in one month and up to 17 pounds in two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results